A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL747 in Subjects With Amyotrophic Lateral Sclerosis
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2020
Price : $35 *
At a glance
- Drugs DNL-747 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Denali Therapeutics Inc
- 09 Jan 2020 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 09 Jan 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Mar 2020.
- 09 Jan 2020 Status changed from recruiting to active, no longer recruiting.